Benchmark Financial Wealth Advisors LLC Acquires 434 Shares of Pfizer Inc. (NYSE:PFE)

Benchmark Financial Wealth Advisors LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 2.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,682 shares of the biopharmaceutical company’s stock after acquiring an additional 434 shares during the quarter. Benchmark Financial Wealth Advisors LLC’s holdings in Pfizer were worth $416,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Onyx Bridge Wealth Group LLC increased its position in shares of Pfizer by 7.4% in the fourth quarter. Onyx Bridge Wealth Group LLC now owns 33,214 shares of the biopharmaceutical company’s stock worth $881,000 after purchasing an additional 2,290 shares during the last quarter. Inman Jager Wealth Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $607,000. Tyche Wealth Partners LLC increased its holdings in shares of Pfizer by 23.1% in the 4th quarter. Tyche Wealth Partners LLC now owns 25,860 shares of the biopharmaceutical company’s stock worth $686,000 after buying an additional 4,859 shares during the last quarter. Tectonic Advisors LLC grew its position in Pfizer by 23.5% in the fourth quarter. Tectonic Advisors LLC now owns 223,686 shares of the biopharmaceutical company’s stock worth $5,934,000 after acquiring an additional 42,570 shares in the last quarter. Finally, Money Concepts Capital Corp increased its stake in Pfizer by 6.5% in the fourth quarter. Money Concepts Capital Corp now owns 208,071 shares of the biopharmaceutical company’s stock valued at $5,520,000 after acquiring an additional 12,724 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.46 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $149.94 billion, a P/E ratio of 35.76, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The firm’s fifty day simple moving average is $26.27 and its 200 day simple moving average is $27.79.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.50%. Pfizer’s payout ratio is currently 232.44%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PFE shares. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.